+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P01330(LIPG Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P01330(LIPG Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

Lipoprotein lipase G (LIPG), also known as endothelial lipase (EL), is a phospholipase A1 enzyme encoded by the *LIPG* gene. Primarily expressed in vascular endothelial cells, it plays a key role in lipid metabolism by hydrolyzing phospholipids on circulating lipoproteins, particularly high-density lipoprotein (HDL), influencing HDL cholesterol levels. Unlike other lipases, LIPG exhibits distinct substrate specificity and regulatory mechanisms, making it a critical focus in cardiovascular and metabolic disease research.

LIPG antibodies are tools used to detect and study the expression, localization, and function of this enzyme. They are widely applied in techniques like Western blotting, immunohistochemistry, and ELISA to investigate LIPG's role in pathologies such as atherosclerosis, inflammation, and cancer. Studies suggest LIPG overexpression may promote endothelial dysfunction and plaque formation, while its inhibition could enhance HDL levels, offering therapeutic potential. Antibodies also aid in exploring LIPG's non-lipolytic functions, including cell signaling and angiogenesis regulation.

Recent research highlights LIPG as a biomarker or therapeutic target, driving demand for high-specificity antibodies. Commercial antibodies target epitopes in LIPG's catalytic domain or N-terminal region, though variability in validation methods requires careful experimental optimization. Ongoing studies aim to clarify its dual roles in lipid homeostasis and disease progression, underscoring the importance of reliable LIPG antibodies in both basic and translational research.